Abstract
Development of post-chemotherapy histiocyte-rich pseudotumor (PHP) is an underrecognized event following therapy in lymphoma patients and may mimic residual tumor using current therapy monitoring protocols. We report a series of 5 patients with PHP along with a review of the literature. In our series, we describe 3 patients with persistent hypermetabolic masses by positron emission tomography-computed tomography, one with persistent terminal ileal nodules on endoscopy, and one with bone marrow involvement, a site not associated with mass-like disease. Twenty-three patients with long-term follow-up were identified from our series and review of the literature. Forty-four percent of patients received additional therapy, and only 4% of patients died of lymphoma. This study illustrates that PHPs are not identified using current lymphoma therapy monitoring algorithms and may result in overtreatment with risk for additional therapy-related complications. The need for confirmatory tissue biopsy in this setting is recommended.
References
1.
Cheson
BD
, Pfistner
B
, Juweid
ME
, Gascoyne
RD
, Specht
L
, Horning
SJ
, International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma
. J Clin Oncol
. 2007
;25
(5
):579
–86
.2.
NCCN Guidelines® & Clinical Resources
. NCCN Clinical Practice Guidelines in Oncology: B-cell Lymphomas Version 4.2020 [Internet]
. National Comprehensive Cancer Network
; 2020
[cited 2020 Oct 20]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.3.
Canellos
GP
. Residual mass in lymphoma may not be residual disease
. J Clin Oncol
. 1988
;6
(6
):931
–3
. .4.
Naumann
R
, Vaic
A
, Beuthien-Baumann
B
, Bredow
J
, Kropp
J
, Kittner
T
, Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma
. Br J Haematol
. 2001
;115
(4
):793
–800
. .5.
Radford
JA
, Cowan
RA
, Flanagan
M
, Dunn
G
, Crowther
D
, Johnson
RJ
, The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin’s disease
. J Clin Oncol
. 1988
;6
(6
):940
–6
. .6.
Surbone
A
, Longo
DL
, Devita
VT
, Ihde
DC
Jr, Duffey
PL
, Jaffe
ES
, Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management
. J Clin Oncol
. 1988
;6
(12
):1832
–7
. .7.
Cheson
BD
, Fisher
RI
, Barrington
SF
, Cavalli
F
, Schwartz
LH
, Zucca
E
, Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano Classification
. J Clin Oncol
. 2014
;32
(27
):3059
–68
.8.
Adams
HJA
, Kwee
TC
. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis
. Eur J Radiol
. 2016
;85
(11
):1963
–70
. .9.
Adams
HJA
, Kwee
TC
. Proportion of false-positive follow-up FDG-PET scans in lymphoma: systematic review and meta-analysis
. Crit Rev Oncol Hematol
. 2019
;141
:73
–81
. .10.
Han
HS
, Escalón
MP
, Hsiao
B
, Serafini
A
, Lossos
IS
. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens
. Ann Oncol
. 2009
;20
(2
):309
–18
. .11.
Isasi
CR
, Lu
P
, Blaufox
MD
. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma
. Cancer
. 2005
;104
(5
):1066
–74
. .12.
Rahman
WT
, Wale
DJ
, Viglianti
BL
, Townsend
DM
, Manganaro
MS
, Gross
MD
, The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging
. Biomed Pharmacother
. 2019 sep
;117
:109168
. .13.
Ashfaq
R
, Timmons
CF
. Xanthomatous pseudotumor of the small intestine following treatment for Burkitt’s lymphoma
. Arch Pathol Lab Med
. 1992
;116
(3
):299
–301
.14.
Chandra
P
, Wen
YH
, Tuli
S
, Raphael
BG
, Amorosi
EL
, Medeiros
LJ
, Postchemotherapy histiocyte-rich pseudotumor involving the spleen
. Am J Clin Pathol
. 2009
;132
(3
):342
–8
. .15.
Chumsri
S
, Tummala
MK
, Khna
AM
, Zhao
XF
, Rapoport
AP
. Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphoma
. Leuk Lymphoma
. 2007
;48
(3
):616
–8
. .16.
Fang
H
, Chuang
HH
, Strati
P
, Hu
S
, Shuai
W
, Medeiros
LJ
, Postchemotherapy histiocyte-rich pseudotumor mimicking residual lymphoma: a report of 11 cases correlating clinicopathologic and radiologic findings
. Am J Surg Pathol
. 2021
;45
(2
):160
–8
. .17.
Otto
M
, Shulkin
BL
, Kundu
M
, Sandlund
JT
, Snyder
SE
, Metzger
ML
. Histiocyte-rich xanthomatous pseudotumor mimicking relapse on positron emission tomography imaging in an adolescent with primary mediastinal diffuse large B-cell lymphoma
. J Pediatr Hematol Oncol
. 2012
;34
(3
):232
–5
. .18.
Ford
CD
, Gabor
F
, Morgan
R
, Dabbas
B
. False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma
. Clin Nucl Med
. 2006
;31
(7
):391
–3
. .19.
Nilak
YD
, Nilak
A
, Shafeek
S
, Rudzki
DZ
, Chapman
J
. Benign histiocyte-rich pseudotumor in post treatment mediastinal Hodgkin’s lymphoma
. Radiol Case Rep
. 2020
;15
(2
):156
–60
. .20.
Abdou
AG
, Kandil
M
, Eldien
MS
, Abdallah
R
. Splenic histiocyte-rich pseudotumor following chemotherapy for non Hodgkin diffuse large B cell lymphoma
. Pathologica
. 2016
;108
(3
):140
–3
.21.
Ahmed
R
, Ghafoor
T
, Akhtar
F
, Hashmi
SN
, Hafeez-ud-Din
, Jamal
S
. Histiocyte rich pseudotumor of spleen/splenic lymph node after chemotherapy for acute lymphoblastic leukemia: a case report
. Pak Armed Forces Med J
. 2014
;64
(1
):178
–80
.22.
Hod
N
, Lantsberg
S
, Anconina
R
, Levin
D
, Nalbandyan
K
, Levi
I
. Postchemotherapy histiocyte-rich pseudotumor of the spleen simulating residual disease in a patient with non-Hodgkin lymphoma on FDG PET/CT
. Clin Nucl Med
. 2019
;44
(6
):e409
–12
. .23.
Singh
AP
, Murray
GP
, Pandey
S
. Benign histiocyte-rich pseudotumor developing postchemotherapy and mimicking residual disease
. Case Rep Pathol
. 2020
;2020
:4674103
. .24.
Rock
KL
, Kono
H
. The inflammatory response to cell death
. Annu Rev Pathol
. 2008
;3
:99
–126
. .25.
Sachet
M
, Liang
YY
, Oehler
R
. The immune response to secondary necrotic cells
. Apoptosis
. 2017
;22
(10
):1189
–204
. .26.
Rekowski
J
, Hüttmann
A
, Schmitz
C
, Müller
SP
, Kurch
L
, Kotzerke
J
, Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: comparison of the Deauville 5-point scale and the ΔSUVmax method
. J Nucl Med
. 2021
;62
(1
):37
–42
.27.
Vetro
C
, Romano
A
, Amico
I
, Conticello
C
, Motta
G
, Figuera
A
, Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow-up
. World J Gastroenterol
. 2014 Sep 28
;20
(36
):12993
–3005
. .28.
Romaguera
JE
, Medeiros
LJ
, Hagemeister
FB
, Fayad
LE
, Rodriguez
MA
, Pro
B
, Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
. Cancer
. 2003
;97
(3
):586
–91
. .29.
Püspök
A
, Raderer
M
, Chott
A
, Dragosics
B
, Gangl
A
, Schöfl
R
. Endoscopic ultrasound in the follow up and response assessment of patients with primary gastric lymphoma
. Gut
. 2002
;51
(5
):691
–4
. .30.
National Comprehensive Cancer Network
. B-Cell Lymphomas (version 3.2021)
. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell_blocks.pdf (accessed 2021 April 19).31.
Lee
HH
, Cho
SG
, Lee
IS
, Cho
HJ
, Jeon
YW
, O
JH
, Mantle cell lymphoma with gastrointestinal involvement and the role of endoscopic examinations
. PLoS One
. 2020
;15
(9
):e0239740
. © 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
